Addition of Levetiracetam May Improve Survival for Glioblastoma
the Cancer Therapy Advisor take:
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy, a recent study published online in the journal Cancer has shown.
For the study, researchers identified 103 patients with primary glioblastoma who received comcomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide. Of those, 56% received levetiracetam during temozolomide chemotherapy for at least 3 months.
Results showed that median progression-free survival was 9.4 months (95% CI: 7.5-11.3) among those who took levetiracetam compared with 6.7 months (95% CI: 5.8-7.6) among those who did not receive the drug (P = 0.010). Median overall survival was 25.7 (95% CI: 21.7-29.7) and 16.7 months (95% CI: 12.1-21.3), respectively (P = 0.027).
The findings suggest that levetiracetam may improve survival in this patient population, but the authors note that a randomized study is warranted.
Previous studies have suggested the chemosensitizing effect of levetiracetam, an antiepileptic drug, but data surrounding survival benefit is lacking.
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC